Literature DB >> 3702874

Purification and characterization of IgE produced by human myeloma cell line, U266.

S Ikeyama, S Nakagawa, M Arakawa, H Sugino, A Kakinuma.   

Abstract

Human IgE was isolated for the first time from the supernatant of the culture fluid of a human myeloma cell line, U266. The purification procedure consisted of salting out from the supernatant with ammonium sulfate, affinity chromatography on a lysine-Sepharose 4B column, ion exchange chromatography on a DEAE-Sephacel column, gel filtration and recycling chromatography on a Sephacryl S-300 column and removal of bovine proteins on an anti-bovine serum rabbit IgG-Sepharose 4B column. One hundred and twenty eight milligrams of IgE was recovered from 461 of culture fluid. The purification was extremely simplified by the introduction of immunoaffinity chromatography using the monoclonal antibody prepared by immunizing a mouse with an IgE preparation obtained by the above method: about 3.3 mg was recovered from 960 ml of culture fluid. The purified preparation was homogeneous as judged by the double-immunodiffusion test and end group analysis. The amino acid and carbohydrate compositions of the preparation coincided with those reported on other preparations obtained from the sera of myeloma patients. Our preparation, however, showed two bands with apparent mol. wts of 240,000 and 230,000 on sodium dodecyl sulfate polyacrylamide gel electrophoresis. When it was reduced with dithiothreitol and analyzed by electrophoresis, it gave two heavy chains and one light chain with apparent mol. wts of 80,000 and 76,000, and 28,000, respectively. On the other hand, the IgE molecule that was synthesized and secreted into the medium in the presence of tunicamycin (0.5 microgram/ml) gave only one heavy chain and one light chain with apparent mol. wts of 62,000 and 28,000, respectively. These results demonstrated that the two IgE molecular species contained in our preparation differed from each other in the carbohydrate moiety in their heavy chains.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3702874     DOI: 10.1016/0161-5890(86)90038-6

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  9 in total

1.  Interaction of human IgE with soluble forms of IgE high affinity receptors.

Authors:  J Liu; J Ruppel; S J Shire
Journal:  Pharm Res       Date:  1997-10       Impact factor: 4.200

2.  In vitro aggregation behavior of a non-amyloidogenic λ light chain dimer deriving from U266 multiple myeloma cells.

Authors:  Paolo Arosio; Marta Owczarz; Thomas Müller-Späth; Paola Rognoni; Marten Beeg; Hua Wu; Mario Salmona; Massimo Morbidelli
Journal:  PLoS One       Date:  2012-03-14       Impact factor: 3.240

3.  Lactate, a putative survival factor for myeloma cells, is incorporated by myeloma cells through monocarboxylate transporters 1.

Authors:  Shiho Fujiwara; Naoko Wada; Yawara Kawano; Yutaka Okuno; Yoshitaka Kikukawa; Shinya Endo; Nao Nishimura; Nina Ueno; Hiroaki Mitsuya; Hiroyuki Hata
Journal:  Exp Hematol Oncol       Date:  2015-04-21

4.  Shikonin, dually functions as a proteasome inhibitor and a necroptosis inducer in multiple myeloma cells.

Authors:  Naoko Wada; Yawara Kawano; Shiho Fujiwara; Yoshitaka Kikukawa; Yutaka Okuno; Masayoshi Tasaki; Mitsuharu Ueda; Yukio Ando; Kazuya Yoshinaga; Masaki Ri; Shinsuke Iida; Takayuki Nakashima; Yukimasa Shiotsu; Hiroaki Mitsuya; Hiroyuki Hata
Journal:  Int J Oncol       Date:  2014-12-19       Impact factor: 5.650

5.  Development of an antibody that neutralizes soluble IgE and eliminates IgE expressing B cells.

Authors:  Andrew C Nyborg; Anna Zacco; Rachel Ettinger; M Jack Borrok; Jie Zhu; Tom Martin; Rob Woods; Christine Kiefer; Michael A Bowen; E Suzanne Cohen; Ronald Herbst; Herren Wu; Steven Coats
Journal:  Cell Mol Immunol       Date:  2015-03-23       Impact factor: 11.530

6.  A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma.

Authors:  E Suzanne Cohen; Claire L Dobson; Helena Käck; Bing Wang; Dorothy A Sims; Christopher O Lloyd; Elizabeth England; D Gareth Rees; Hongwei Guo; Sophia N Karagiannis; Siobhan O'Brien; Sofia Persdotter; Helena Ekdahl; Robin Butler; Feenagh Keyes; Sarah Oakley; Mats Carlsson; Emmanuel Briend; Trevor Wilkinson; Ian K Anderson; Phillip D Monk; Karin von Wachenfeldt; Per-Olof F Eriksson; Hannah J Gould; Tristan J Vaughan; Richard D May
Journal:  MAbs       Date:  2014-02-28       Impact factor: 5.857

7.  PDK1 inhibition is a novel therapeutic target in multiple myeloma.

Authors:  S Fujiwara; Y Kawano; H Yuki; Y Okuno; K Nosaka; H Mitsuya; H Hata
Journal:  Br J Cancer       Date:  2012-11-29       Impact factor: 7.640

8.  EBV epigenetically suppresses the B cell-to-plasma cell differentiation pathway while establishing long-term latency.

Authors:  Christine T Styles; Quentin Bazot; Gillian A Parker; Robert E White; Kostas Paschos; Martin J Allday
Journal:  PLoS Biol       Date:  2017-08-03       Impact factor: 8.029

9.  Bufalin induces DNA damage response under hypoxic condition in myeloma cells.

Authors:  Eri Fujii; Yuki Inada; Misaki Kakoki; Nao Nishimura; Shinya Endo; Shiho Fujiwara; Naoko Wada; Yawara Kawano; Yutaka Okuno; Toshiya Sugimoto; Hiroyuki Hata
Journal:  Oncol Lett       Date:  2018-02-21       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.